| Literature DB >> 28955884 |
Yousuke Kouno1,2, Makoto Anraku1,3, Keishi Yamasaki1,3, Yoshiro Okayama2, Daisuke Iohara1, Hedeaki Nakamura4, Toru Maruyama4, Fumitoshi Hirayama1,3, Ulrich Kragh-Hansen5, Masaki Otagiri1,3.
Abstract
Sodium octanoate and N-acetyl-L-tryptophan (N-AcTrp) are widely used as stabilizers during pasteurization and storage of albumin products. However, as compared with N-AcTrp, N-acetyl-L-methionine (N-AcMet) is superior in protecting albumin exposed to light during storage. Here, we examine, whether N-AcMet also is better than N-AcTrp to protect albumin against oxidation. Recombinant human serum albumin (rHSA) without and with N-AcMet or N-AcTrp was oxidized by using chloramine-T (CT) as a model compound for mimicking oxidative stress. Oxidation of rHSA was examined by determining carbonyl groups and advanced oxidation protein products. Structural changes were studied by native-PAGE, circular dichroism, intrinsic fluorescence and differential scanning calorimetry. The anti-oxidant capacity of CT-treated rHSA was quantified by its ability to scavenge peroxynitrite and the hydroxyl radical. The pharmacokinetics of indocyanine green-labeled albumin preparations was studied in male mice. We found that the number of chemical modifications and the structural changes of rHSA were significantly smaller in the presence of N-AcMet than in the presence of N-AcTrp. The anti-oxidant properties of CT-exposed rHSA were best protected by adding N-AcMet. Finally, N-AcMet is superior in preserving the normal pharmacokinetics of rHSA. Thus, N-AcMet is superior to N-AcTrp in protecting albumin preparations against oxidation. In addition, N-AcMet is probable also useful for protecting other proteins. Therefore, N-AcMet should be useful as a new and effective stabilizer and antioxidant for albumin isolated from blood, rHSA, albumin-fusion proteins and for preparations of rHSA-therapeutic complexes.Entities:
Keywords: CD, circular dichroism; CT, chloramine-T; DSC, differential scanning calorimetry; HSA, human serum albumin; Human serum albumin; N-AcMet, N-acetyl-L-methionine; N-AcTrp, N-acetyl-L-tryptophan; N-Acetyl-L-Methionine; N-Acetyl-L-Tryptophan; Oct, octanoate; Oxidation; Pharmacokinetics; ROS, reactive oxygen species; Structural Changes; rHSA, recombinant HSA
Year: 2016 PMID: 28955884 PMCID: PMC5600351 DOI: 10.1016/j.bbrep.2016.04.011
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Fig. 1AOPP content of non-treated rHSA (control) and oxidized rHSAs. The concentration of rHSA was 100 µM. Each column represents the mean ± S.D. (n=4). ⁎⁎P<0.01, compared with control. ##P<0.01, compared with CT-rHSA additive (-). ††P<0.01, compared with CT-rHSA + N-AcTrp.
Fig. 2(A) Carbonyl content of non-treated rHSA (control) and oxidized rHSAs. The concentration of rHSA was 0.2 mM and that of each additive was 1 mM. Each column represents the mean ± S.D. (n =3). ⁎⁎P<0.01, compared with control. ##P<0.01, compared with CT-rHSA additive (-). ††P<0.01, compared with CT-rHSA + N-AcTrp. (B) Native-PAGE electrophoresis. The concentration of rHSA was 0.1 mM and that of each additive was 0.5 mM. (C) Western blots and staining with Oxyblot Kit reagents. (D) Level of rHSA oxidation as determined by densitometry ratios between DNP area and corresponding protein area. Each column represents the mean ± S.D. (n=4). ##P<0.01, compared with CT-rHSA additive (-). ††P<0.01, compared with CT-rHSA + N-AcTrp.
Fig. 3Relative peroxynitrite scavenging activity of non-treated rHSA (control) and oxidized rHSAs. The concentration of rHSA was 25 µM. Each column represents the mean ± S. D. (n=3). ⁎⁎P<0.01, compared with control. ##P<0.01, compared with CT-rHSA additive (-). ††P<0.01, compared with CT-rHSA + N-AcTrp.
Fig. 4Relative hydroxyl radical scavenging activity of non-treated rHSA (control) and oxidized rHSAs. The concentration of rHSA was 50 µM. Each column represents the mean ± S. D. (n=3). ⁎⁎P<0.01, compared with control. ##P<0.01, compared with CT-rHSA additive (-). ††P<0.01, compared with CT-rHSA + N-AcTrp.
Fig. 5Thermogram of non-treated rHSA (control) and oxidized rHSAs obtained by DSC. (1) control, (2) CT-rHSA additive (-), (3) CT-rHSA + N-AcMet, (4) CT-rHSA + N-AcTrp dissolved in sodium phosphate buffer, pH 7.4. The protein concentration was 20 µM.
Thermodynamic data obtained from DSC of different rHSA samples after CT-induced oxidation.a
| Protein samples | Tm (°C) | ΔHcal (kcal/mol) | ΔHv (kcal/mol) | ΔHv/ΔHcal |
|---|---|---|---|---|
| Control | 60.8±0.09 | 126±3.0 | 83.8±4.1 | 0.66±0.20 |
| CT-rHSA additives (-) | 61.7±0.07 | 48.2±2.5 | 56.9±3.4 | 1.18±0.10 |
| CT-rHSA + N-AcMet | 61.2±0.05 | 91.9±4.9 | 64.1±2.9 | 0.70±0.18 |
| CT-rHSA + N-AcTrp | 62.3±0.10 | 54.3±3.9 | 57.4±1.9 | 1.06±2.9 |
The concentration of rHSA was 20 µM and that of each additive was 100 µM. The results are means ± S. D. (n=3).
P<0.01, compared with control.
P<0.01, compared with CT-rHSA additive (-).
P<0.05, compared with CT-rHSA + N-AcTrp.
Fig. 6Far-UV CD spectra of non-treated rHSA (control) and oxidized rHSAs. (1) control, (2) CT-rHSA additive (-), (3) CT-rHSA + N-AcMet, (4) CT-rHSA + N-AcTrp dissolved in sodium phosphate buffer, pH 7.4. The protein concentration was 10 µM.
Fig. 7Intrinsic fluorescence spectra of non-treated rHSA (control) and oxidized rHSAs. (1) control, (2) CT-rHSA additive (-), (3) CT-rHSA + N-AcMet, (4) CT-rHSA + N-AcTrp dissolved in sodium phosphate buffer, pH 7.4. The protein concentration was 2 µM. au, arbitrary units.
Fig. 8In vivo pharmacokinetics of ICG-labeled, non-treated rHSA (control) and oxidized rHSAs. Each data point represents the mean ± S.D. (n=6). ⁎⁎P<0.01, compared with control. ##P<0.01, compared with CT-rHSA additive (-). ††P<0.01, compared with CT-rHSA + N-AcTrp.